Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
DNA vaccine | 1 |
Top 5 Target | Count |
---|---|
GNB1L x LMLN | 1 |
DNMT1 x MDM2 x Nrf2 x RBM3 x TGF-β x TLR4 x VEGF | 1 |
Mechanism DNMT1 inhibitors [+6] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GNB1L modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Jan 2025 |
Sponsor / Collaborator |
Start Date21 Nov 2024 |
Sponsor / Collaborator |
Start Date06 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Leishmania multi-epitope vaccine(Shiraz University of Medical Sciences) ( GNB1L x LMLN ) | Leishmaniasis More | Preclinical |
Curcumin ( DNMT1 x MDM2 x Nrf2 x RBM3 x TGF-β x TLR4 x VEGF ) | Parkinson Disease More | Preclinical |
Fumaria Parviflora L. | Kidney Failure, Chronic More | Pending |
Silybum marianum extract | - | Pending |
Sumac Extract | Weight Gain More | Pending |